β-adrenergic antagonist and low efficacy partial agonist; does not affect resting cardiac parameters.
Sold with the permission of AstraZeneca UK Ltd.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 354.41. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.82 mL||14.11 mL||28.22 mL|
|5 mM||0.56 mL||2.82 mL||5.64 mL|
|10 mM||0.28 mL||1.41 mL||2.82 mL|
|50 mM||0.06 mL||0.28 mL||0.56 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
If you know of a relevant reference for ICI 89406, please let us know.
View Related Products by Product Action
Keywords: β-adrenoceptor beta-adrenoceptor b-adrenoceptor β-adrenergic beta-adrenergic b-adrenergic antagonists Receptors Non-Selective ICI89406 AstraZeneca Non-selective Adrenergic Beta Receptors
2 Citations for ICI 89406
Citations are publications that use Tocris products. Selected citations for ICI 89406 include:
Mistry et al (2013) Synthesis and in vitro and in vivo characterization of highly β1-selective β-adrenoceptor partial agonists. J Med Chem 56 3852 PMID: 23614528
Kaya et al (2009) Coupling of β2-adrenoceptors to XLαs and Gαs: a new insight into ligand-induced G protein activation. J Pharmacol Exp Ther 329 350 PMID: 19144685
Do you know of a great paper that uses ICI 89406 from Tocris? If so please let us know.
Literature in this Area
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.